SG11201903659WA - Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications - Google Patents
Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indicationsInfo
- Publication number
- SG11201903659WA SG11201903659WA SG11201903659WA SG11201903659WA SG11201903659WA SG 11201903659W A SG11201903659W A SG 11201903659WA SG 11201903659W A SG11201903659W A SG 11201903659WA SG 11201903659W A SG11201903659W A SG 11201903659WA SG 11201903659W A SG11201903659W A SG 11201903659WA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- aulx
- ouates
- les
- plane
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 101710104976 Interferon gamma-related Proteins 0.000 title 1
- 102000056303 Ferlin Human genes 0.000 abstract 1
- 108700036130 Ferlin Proteins 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/249—Interferons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Transplantation (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662411783P | 2016-10-24 | 2016-10-24 | |
| PCT/IB2017/001427 WO2018078442A2 (en) | 2016-10-24 | 2017-10-24 | Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201903659WA true SG11201903659WA (en) | 2019-05-30 |
Family
ID=60957345
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201903659WA SG11201903659WA (en) | 2016-10-24 | 2017-10-24 | Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP3528845A2 (ko) |
| JP (2) | JP2019532970A (ko) |
| KR (1) | KR20190071785A (ko) |
| CN (1) | CN110167593A (ko) |
| AU (1) | AU2017352033A1 (ko) |
| BR (1) | BR112019008156A2 (ko) |
| CA (1) | CA3041434A1 (ko) |
| EA (1) | EA201990930A1 (ko) |
| IL (1) | IL266174B1 (ko) |
| MX (1) | MX2019004766A (ko) |
| SG (1) | SG11201903659WA (ko) |
| WO (1) | WO2018078442A2 (ko) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118146379A (zh) * | 2016-04-26 | 2024-06-07 | 科济生物医药（上海）有限公司 | 一种改善免疫应答细胞功能的方法 |
| EP3488851A1 (en) * | 2018-10-03 | 2019-05-29 | AVM Biotechnology, LLC | Immunoablative therapies |
| WO2021185832A1 (en) | 2020-03-16 | 2021-09-23 | Swedish Orphan Biovitrum Ag | New therapeutic treatment |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US6329511B1 (en) * | 1998-12-01 | 2001-12-11 | Protein Design Labs, Inc. | Humanized antibodies to γ-interferon |
| BRPI0607238B8 (pt) | 2005-01-27 | 2021-05-25 | Novimmune Sa | anticorpos anti-interferon gama humano, usos dos mesmos na preparação de medicamentos e composições farmacêuticas |
| KR20140097336A (ko) * | 2011-11-23 | 2014-08-06 | 암젠 인크 | 인터페론 감마에 대한 항체를 이용한 치료 방법 |
| CA2985001A1 (en) * | 2015-05-07 | 2016-11-10 | Novimmune Sa | Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of cxcl9 and other biomarkers |
-
2017
- 2017-10-24 MX MX2019004766A patent/MX2019004766A/es unknown
- 2017-10-24 WO PCT/IB2017/001427 patent/WO2018078442A2/en active Application Filing
- 2017-10-24 EA EA201990930A patent/EA201990930A1/ru unknown
- 2017-10-24 AU AU2017352033A patent/AU2017352033A1/en active Pending
- 2017-10-24 BR BR112019008156A patent/BR112019008156A2/pt unknown
- 2017-10-24 IL IL266174A patent/IL266174B1/en unknown
- 2017-10-24 KR KR1020197014837A patent/KR20190071785A/ko not_active IP Right Cessation
- 2017-10-24 EP EP17829009.4A patent/EP3528845A2/en active Pending
- 2017-10-24 JP JP2019521706A patent/JP2019532970A/ja not_active Withdrawn
- 2017-10-24 CA CA3041434A patent/CA3041434A1/en active Pending
- 2017-10-24 CN CN201780080221.6A patent/CN110167593A/zh active Pending
- 2017-10-24 SG SG11201903659WA patent/SG11201903659WA/en unknown
-
2022
- 2022-10-28 JP JP2022173528A patent/JP2022187025A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017352033A1 (en) | 2019-06-06 |
| EA201990930A1 (ru) | 2019-11-29 |
| CN110167593A (zh) | 2019-08-23 |
| CA3041434A1 (en) | 2018-05-03 |
| KR20190071785A (ko) | 2019-06-24 |
| WO2018078442A3 (en) | 2018-08-23 |
| IL266174A (en) | 2019-06-30 |
| JP2022187025A (ja) | 2022-12-15 |
| IL266174B1 (en) | 2024-06-01 |
| WO2018078442A2 (en) | 2018-05-03 |
| MX2019004766A (es) | 2019-09-27 |
| JP2019532970A (ja) | 2019-11-14 |
| BR112019008156A2 (pt) | 2019-07-02 |
| EP3528845A2 (en) | 2019-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201909949XA (en) | Targeted immunotolerance | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201910027YA (en) | Bispecific antibody against ox40 and ctla-4 | |
| SG11201811432WA (en) | Rna for cancer therapy | |
| SG11201906192SA (en) | Methods of treating cancer with anti-pd-1 antibodies | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201810525XA (en) | Anti-gitr antibodies and uses thereof | |
| SG11201903604PA (en) | Iot security service | |
| SG11201807573VA (en) | Methods for providing single-stranded rna | |
| SG11201810983PA (en) | Novel heterocyclic derivatives useful as shp2 inhibitors | |
| SG11201907023UA (en) | Method of reducing neutropenia | |
| SG11201811564QA (en) | Methods of treating ovarian cancer | |
| SG11201907650RA (en) | Personal therapy and exercise monitoring and oversight devices, systems, and related methods | |
| SG11201811230RA (en) | Compositions and methods for reducing ocular neovascularization | |
| SG11201810872UA (en) | Composition and method for reducing neutropenia | |
| SG11201808713YA (en) | Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier | |
| SG11201805149XA (en) | Compositions comprising 15-hepe and methods of using the same | |
| SG11201805001UA (en) | Method of treating influenza a | |
| SG11201907774VA (en) | Sulfoximine glycosidase inhibitors | |
| SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
| SG11201907420VA (en) | Inhibition of smarca2 for treatment of cancer | |
| SG11201810786RA (en) | [bis(trihydrocarbylsilyl)aminosilyl]-functionalized styrene and a method for its preparation | |
| SG11201809875VA (en) | Compositions and methods for treating spinal muscular atrophy | |
| SG11201807949WA (en) | Engineered immunoglobulins with altered fcrn binding | |
| SG11201901438VA (en) | Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate |